Deregulation of EGFR/VEGF/HIF-1a signaling pathway in colon adenocarcinoma based on tissue microarrays analysis

Journal of B.U.ON.

Volumn 15, Issue 1, 2010, Pages 107-115

  Rigopoulos, D N ^a   Tsiambas, Evangelos ^b   Lazaris, A C ^b   Kavantzas, N ^b   Papazachariou, ^c   Kravvaritis, C ^d   Tsounis, D ^e   Koliopoulou, A ^f   Athanassiou, A E ^g   Karameris, A ^h   Manaios, L ^d   Sergentanis, T N ^b   Patsouris, E ^b  

^a 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Larnaca General Hospital   (Cyprus)

^d Department of Forensic Service ^*  (Greece)

^e 251 Air Force Hospital   (Greece)

^f EVANGELISMOS HOSPITAL   (Greece)

^g METAXA CANCER HOSPITAL   (Greece)

^h NIMTS HOSPITAL   (Greece)

Author keywords

Colon adenocarcinoma; Growth factors; Hybridization; Immunohistochemistry; Microarrays

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MONOCLONAL ANTIBODY; VASCULOTROPIN;

ADVANCED CANCER; AGED; ANEUPLOIDY; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CENTROMERE; CHROMOGENIC IN SITU HYBRIDIZATION; CHROMOSOMAL INSTABILITY; CHROMOSOME 7; COLON ADENOCARCINOMA; EGFR GENE; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE PROBE; GENETIC TRANSCRIPTION; HIF 1ALPHA GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEPTOR GENE; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; VEGF GENE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANEUPLOIDY; CHROMOSOMAL INSTABILITY; CHROMOSOMES, HUMAN, PAIR 7; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; NEOPLASM STAGING; PARAFFIN EMBEDDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77950966388     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Arteaga Cl. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19: 32-40.
2. Nicholson RI, Gee JM, Harper ME.EGFR and cancer prognosis. Eur J Cancer 2001; 37: S9-S15.
3. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027.
4. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172-187.
5. Marquez A, Wu R, Zhao J, Tao J, Shi Z. Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn Mol Pathol 2004; 13: 1-8.
6. Prewett MC, Hooper AT, Bassi R. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002; 8: 994-1003.
7. Wiedmann MW, Casa K. Molecular targeted therapy for gastro-intestinal cancer. Curr Cancer Drug Targets 2005; 5: 171-193. (Pubitemid 40694859)
8. Vallbohmer D, Zhang W, Gordon M. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005; 23: 3536-3544.
9. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonist in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-2799. (Pubitemid 46606324)
10. Moroni M, Veronese S, Benvenuti S. Gene copy number for epidermal growth factor receptor EGFR and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-286. (Pubitemid 40590264)
11. O'dwyer PJ, Benson AB. Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin Oncol 2002; 29: 10-17.
12. Veikkola T, Atitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999; 9: 211-220.
13. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-4380.
14. Strieter RM. Masters of angiogenesis. Nat Med 2005; 11: 925-927.
15. Kuwai T, Kitadai Y, Tanaka S. Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer 2003; 105: 176-181. (Pubitemid 36505317)
16. Duff SE, Jeriorska M, Rosa D. Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. Eur J Cancer 2006; 42: 112-117. (Pubitemid 41814541)
17. Wu W, Shu X, Hovsepyan H. VEGF receptor expression and signaling in human bladder tumors. Oncogene 2003; 22: 3361-3370. (Pubitemid 36713733)
18. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10: 415-427. (Pubitemid 38173977)
19. Gelman A, Desnoyers R, Cagir B. Colorectal cancer staging and adjuvant chemotherapy. Expert Opin Pharmacother 2000; 1: 737-755.
20. Chung KY, Shia J, Kemeny NE. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 3: 1803-1810. (Pubitemid 46211358)
21. Saltz L, Meropol N, Loecher PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208. (Pubitemid 41079832)
22. Bartlett JM, Going JJ, Mallon EA. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 2001; 195: 422-428.
23. Thomson TA, Hayes MM, Spinelli JJ. HER-2/neu in breast cancer: inter-observer variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 2001; 14: 1079-1086.
24. Blanchot-Jossic F, Jarry A, Masson. Up-regulated expression of ADAM 17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J Pathol 2005; 207: 156-163. (Pubitemid 41404146)
25. Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo V. Epidermal growth factor receptor, c-met, b-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 2004; 10: 3069-3075. (Pubitemid 38619685)
26. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer stage IV colon adenocarcinoma. Cancer 2001; 92: 1331-1346.
27. Moon WS, Chang KJ, Majumdar AP, Tarnawski AS. Reduced expression of epidermal growth factor receptor - related protein in hepatocellular carcinoma: implications for cancer growth. Digestion 2004; 69: 219-224.
28. Yang JL, Qu XJ, Russell PJ, Goldstein D. Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon alpha. Gut 2004; 53: 123-129. (Pubitemid 38083020)
29. Arnould L, Denoux Y, McGrogan G. Agreement between chromogenic in situ hybridization (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 2003; 88: 1587-1591. (Pubitemid 36713787)
30. Clarke LE, Leitzel K, Smith J, Ali SM, Lipton A. Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RTPCR Int J Oncol 2003; 22: 425-430.
31. Lagerstedt KK, Staaf J, Jonsson G. Tumor genome wide DNA alterations assessed by array CGH in patients with poor and excellent survival following operation for colorectal cancer. Cancer Inf 2007; 3: 351-365.
32. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor la (HIF-1a) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995-4004. (Pubitemid 32476461)
33. Mizukami Y, Fujiki K, Duerr EM. Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J Biol Chem 2006; 19: 13957-13963. (Pubitemid 43848321)
34. Mizukami Y, Li J, Zhang X, Zimmer MA, Iliopoulos O, Chung DC. Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res 2004; 64: 1765-1772. (Pubitemid 38428700)
35. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Disc 2004; 3: 391-400. (Pubitemid 38618122)
36. Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ. 1 alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor- 1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther 2007; 6: 1433-1439. (Pubitemid 46712007)
37. Merighi S, Benini A, Mirandola P. Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol 2007; 72: 395-406. (Pubitemid 47124120)
38. Madbouly K, Senagore A, Mukerjee A, Delaney C, Connor J, Fazio V. Does immunostaining effectively upstage colorectal cancer by identifying micrometastatic nodal disease? Int J Colorectal Dis 2007; 22: 39-48.
39. Molina J, Adjei A. The Ras/Raf/MAPK Pathway. J Thorac Oncol 2006; 1: 7-9.